Raben David 4

What Happened David Raben, Chief Medical Officer of Bicara Therapeutics (BCAX), was granted a derivative award of 100,000 shares on February 2, 2026. The filing reports the acquisition as a derivative award at $0.00 per share (total reported value $0), indicating a compensation grant rather than an open-market purchase. This is an award/grant (code A) — not a sale or exercise — and does not involve immediate cash proceeds or an immediate transfer of vested shares.

Key Details

• Transaction date: February 2, 2026; Form 4 filed February 4, 2026 (two days after the transaction date).
• Reported terms: 100,000 shares acquired as a derivative award at $0.00 per share (total $0 reported).
• Shares owned after the transaction: not specified in the provided filing summary.
• Footnote: The shares underlying this option vest in sixteen equal quarterly installments beginning after February 2, 2026, subject to Raben’s continued service on each vesting date (per filing footnote F1).
• Timeliness: Filed Feb 4 for a Feb 2 transaction — appears to meet the standard 2-business-day Form 4 reporting window.

Context This grant is a compensation award (likely an option/award) that vests over four years in quarterly installments; the recipient does not immediately own tradable shares until portions vest. Such grants are routine for executive compensation and do not directly signal a buy/sell decision in the open market.